About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 2

A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients

A Phase II Randomized, Blinded, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Different Regimens of 1592U89 Monotherapy Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy-Naive Patients

NCT00002390•Glaxo Wellcome

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

HIV Infections

Interventions

Abacavir sulfate

Locations

6

France

Locations (6)

Group Hospier Pitie-Salpetriere / Maladies Infec et Trop

Paris, France

Groupe Hospitalier Bichat-Claude Bernard

Paris, France

Hopital de Purpan / CHU de Rangueil / Medecine Interue

Toulouse, France

Hopital de Purpan / Service du Professeur Auvergnat

Toulouse, France

Universitat Erlangen

Erlangen, Germany

Universitatsklinikurn Frankfurt

Frankfurt, Germany

Key Dates

Last Updated

June 24, 2005

Related Studies

RECRUITINGPhase 3

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

NCT07428330

Cervix CancerHIV Infections+1 more

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

NCT07225530

HIV InfectionsHPV Infection+1 more

RECRUITINGPhase 1

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

NCT06665646

Comprehensive HIV and Harm Prevention Via Telehealth

NCT05897099

View all related studies

Sponsors

Lead Sponsor

Glaxo Wellcome

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2005Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions